CureVac aims to raise up to $245 million in U.S. IPO

This post was originally published on this site

The biotech firm said on Monday it plans to offer a total of up to 15.33 million new shares, adding the shares will likely be priced at between $14.00 and $16.00 apiece.

Bank of America (NYSE:BAC), Jefferies (NYSE:JEF) and Credit Suisse (SIX:CSGN) are acting as joint book-runners, with Berenberg and Kempen & Co acting as passive book-running managers, it added.

The proceeds will fund the development of an mRNA-based COVID-19 vaccine, the ramp-up of manufacturing capabilities, its oncology drug development and the development of a rabies vaccine, among other ventures, according to the statement.

The group, which is controlled by Software firm SAP co-founder Dietmar Hopp and also backed by the foundation of Microsoft (NASDAQ:MSFT) co-founder Bill Gates, initially flagged plans to go public on July 24.

It previously won the German state, British drugmaker GlaxoSmithKline (NYSE:GSK) and the Qatar Investment Authority as investors funding its growth.

Hopp has agreed to purchase shares worth 100 million euros ($117 million) at the IPO.

Add Comment